NAFDAC alerts Nigerians to recall of Amoxycillin batch over ‘adverse effects’

The National Agency for Food and Drugs Administration and Control (NAFDAC) has notified Nigerians of the recall of one batch of Deekins Amoxycillin 500mg capsule manufactured by Ecomed Pharma Ltd.

Amoxicillin is a penicillin antibiotic used for treating bacterial infections like tonsillitis, bronchitis and infections of the ear, nose, throat, skin, or urinary tract.

In a statement on Wednesday, the agency said the batch is being recalled following reports of adverse reactions.

NAFDAC said the product with batch number 4C639001 was produced in March 2024 and expires in February 2027.

“According to Ecomed Pharma Ltd, reports of serious adverse drug reactions were received from a hospital that reported three cases of serious adverse drug reactions from patients administered with the batch of Deekins Amoxycillin 500mg capsule,” the statement reads.

“An adverse reaction to drugs may be life-threatening, may require hospitalization or prolongation of existing hospitalization, result in persistent or significant disability or incapacity, or is a birth defect or death in fatal cases.”

NAFDAC implored distributors, healthcare providers, and patients to exercise caution and vigilance within the supply chain to avoid distribution, administration, and use of the affected product.

“All medical products must be obtained from authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked,” the statement reads.

“Anyone in possession of the affected lot is advised to immediately discontinue the sale or use and submit stock to the nearest NAFDAC office.

“If you have used this product, or someone you know has used it, or suffered any adverse reaction/event after use, are advised to seek immediate medical advice from a qualified healthcare professional.

“Healthcare professionals and consumers are advised to report any suspicion of substandard and falsified medicines to the nearest NAFDAC office, NAFDAC on 0800-162-3322 or via email: [email protected].”